Current concepts in the treatment of giant cell tumour of bone. Issue 4 (July 2020)

• Record Type: Journal Article
• Authors: van der Heijden, Lizz; Dijkstra, Sander; van de Sande, Michiel; Gelderblom, Hans
• Is Part Of: Current opinion in oncology. Volume 32:Issue 4(2020:Jul.)
• Publication Date: 2020-07
• Subjects: bisphosphonates -- curettage -- denosumab -- giant cell tumour of bone -- local recurrence -- neoadjuvant; Oncology -- Periodicals; 616.994
• DOI: 10.1097/CCO.0000000000000645
• Languages: English
• ISSNs: 1040-8746

Abstract

Abstract : Purpose of review: Giant cell tumour of bone (GCTB) is an intermediate, locally aggressive primary bone tumour. In addition to local therapy, new drugs became available for this disease. Denosumab, a receptor activator of nuclear factor κ-B-ligand inhibitor, was introduced as systemic targeted therapy for advanced or inoperable and metastatic GCTB. Also, the bisphosphonate zoledronic acid has activity in GCTB by directly targeting the neoplastic stromal cells. Recent findings: In a small RCT, bisphosphonates were successful in controlling tumour growth and a higher apoptotic index of tumour cells was seen after zoledronic acid versus controls. Although bisphosphonate-loaded bone cement has not been studied to a large extent, it does not seem harmful and may constitute a logical local adjuvant. From the largest clinical trial to date, the risk-to-benefit ratio for denosumab in patients with advanced GCTB remains favourable, also in facilitating less morbid surgery. Concerns have arisen that recurrence rates would be higher than after conventional treatment, ranging from 20 to 100% in a systematic review, although this may be because of bias. H3F3A (G34W) driver mutations are helpful in the differentiation between GCTB and other giant cell-containing malignancies. H3.3-G34W proved sufficient to drive tumourigenesis. The cumulative incidence of malignancy in GCTB is estimated at 4%, of which primary malignancy 1.6% and secondary malignancy 2.4%, the latter mainly after radiation. To date, a potential causal relationship between denosumab and pulmonary metastases has not been confirmed; if they do not behave indolently, it would be advised to reassess diagnosis and consider malignancy. Summary: Denosumab remains a highly effective treatment option for patients with advanced GCTB. A short duration of 2–4 months neoadjuvant denosumab is advised to facilitate less morbid surgery and prevent incomplete curettage by macroscopic tumour alterations. Reduced dose intensity is being studied to reduce long term side-effects. Further research on bisphosphonates and other targets including H3.3-G34W remains warranted.